6-(Arylaminomethyl) Isoquinolines as Enzyme Inhibitors and Their Preparation:
A Patent Highlight of Factor XIIa Inhibitors

Al‐Horani, Rami A.

doi:10.2174/1871525721666230126114224

Cited by 1 publication

(1 citation statement)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Very few potent and selective small molecule inhibitors of FXIIa are in development (Figure ). − We previously reported inhibitor “ RA ” as a potent and selective inhibitor of FXIIa . In this study, we combined a small library of 32 triazole and triazole-like analogs of inhibitor RA to be evaluated for FXIIa inhibition using a chromogenic substrate hydrolysis assay under physiological conditions.…”

Section: Introductionmentioning

confidence: 99%

New Triazole-Based Potent Inhibitors of Human Factor XIIa as Anticoagulants

Woodland,

Thompson,

Lipford

et al. 2024

ACS Omega

Self Cite

View full text Add to dashboard Cite

Factor XIIa (FXIIa) functions as a plasma serine protease within the contact activation pathway. Various animal models have indicated a substantial role for FXIIa in thromboembolic diseases. Interestingly, individuals and animals with FXII deficiency seem to maintain normal hemostasis. Consequently, inhibiting FXIIa could potentially offer a viable therapeutic approach for achieving effective and safer anticoagulation without the bleeding risks associated with the existing anticoagulants. Despite the potential, only a limited number of small molecule inhibitors targeting human FXIIa have been documented. Thus, we combined a small library of 32 triazole and triazole-like molecules to be evaluated for FXIIa inhibition by using a chromogenic substrate hydrolysis assay under physiological conditions. Initial screening at 200 μM involved 18 small molecules, revealing that 4 molecules inhibited FXIIa more than 20%. In addition to being the most potent inhibitor identified in the first round, inhibitor 8 also exhibited a substantial margin of selectivity against related serine proteases, including factors XIa, Xa, and IXa. However, the molecule also inhibited thrombin with a similar potency. It also prolonged the clotting time of human plasma, as was determined in the activated partial thromboplastin time and prothrombin time assays. Subsequent structure−activity relationship studies led to the identification of several inhibitors with submicromolar activity, among which inhibitor 22 appears to demonstrate significant selectivity not only over factors IXa, Xa, and XIa, but also over thrombin. In summary, this study introduces novel triazole-based small molecules, specifically compounds 8 and 22, identified as potent and selective inhibitors of human FXIIa. The aim is to advance these inhibitors for further development as anticoagulants to provide a more effective and safer approach to preventing and/or treating thromboembolic diseases.

show abstract